• search
For Quick Alerts
For Daily Alerts

Bharat Biotech's COVID-19 vaccine Covaxin gets approval for phase 3 trials


New Delhi, Oct 22: Covaxin, an indigenously developed vaccine candidate by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has got clearance for phase three trials in India.

 Bharat Biotechs COVID-19 vaccine Covaxin gets approval for phase 3 trials

On October 2, the pharma company had applied to the Drugs Controller General of India (DCGI) asking its permission to conduct Phase 3 trials for its vaccine candidate.

"After detailed deliberation and based on the available evidences, the committee recommended for grant of permission to conduct Phase III clinical trial," the panel said in a statement.

India in talks to join COVAX global vaccine allocation plan: WHO

Covaxin is the first indigenous vaccine developed by India against Covid-19 and is derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune.

    Bihar Polls 2020: BJP announces free vaccine for all in Bihar, faces heat | Oneindia News

    Its trial for phase one and two was already underway after receiving the approval from Drugs Controller General of India (DCGI).

    Meanwhile, more than 100 coronavirus vaccine candidates are in different stages all across the world.

    Almost three months back in July, BBIL was allowed to hold phase I and phase II of the human clinical trials.

    For Daily Alerts
    Get Instant News Updates
    Notification Settings X
    Time Settings
    Clear Notification X
    Do you want to clear all the notifications from your inbox?
    Settings X